Current IBD therapies such as corticosteroids, and 5-aminosalicylate, modulate colitis by blocking mammalian target of the rapamycin complex 1 (mTORC1), which results in decreasing HIF-1α expression and thereby glycolysis (67, 68). Here, HIF1A is linked to inflammatory bowel disease.